Skip to content

Jacqueline Plau

Pau-PDDS23-scaled-e1675277433510
Predoctoral Fellowship in Drug Discovery, 2023 Case Western Reserve University

Developing a Therapeutic Strategy for Blinding Eye Diseases

Summary

When light hits our eyes, special cells called photoreceptors convert the light into electrical signals for our brains, enabling us to see. Vitamin A plays a crucial role in this visual process. However, sometimes the process goes awry and causes the accumulation of toxic byproducts of Vitamin A in the eye. This is found in common eye diseases such as age-related macular degeneration (AMD) and Stargardt disease and can ultimately lead to blindness. Stopping the overproduction of these byproducts may be a potential approach for treating these diseases. My project describes a new methodology for controlling Vitamin A byproducts in the eye by developing drug candidates and assessing their potential effects in animal models of human eye diseases.  

Learn more in this Q&A with Plau.

To me, being a PhRMA Foundation awardee means that genuine hard work and effort can and will pay off — no matter where you come from or whom you know. I owe the PhRMA Foundation not only my deepest gratitude but also my utmost respect.

Jacqueline Plau

Related Links

PhRMA Foundation
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.